NewsEvents

Your Yourlocation: Home > Clinical observation of tiotropium bromide(136310-93-5) combined with noninvasive ventilation in the treatment of chronic obstructive pulmonary disease in 30 cases

To investigate the clinical efficacy of tiotropium bromide(136310-93-5) combined with bi-level positive airway pressure (BiPAP) on the stable phase of chronic obstructive pulmonary disease (COPD). Methods: Sixty patients with COPD were randomly divided into experimental group and control group. 0.1 g, 2 times /d, treatment for 13 weeks; test group in accordance with the above treatment at the same time by adding tiotropium bromide  inhalant 18 ug, 1 suction /d, using Handihaler inhalation device, combined with non-invasive ventilation (IPAP) 10-20 cm HO (1 cm HO = 0.098 kPa), exhalation pressure (EPAP) 4-6 cmHO, oxygen concentration (FiO) 25% and the ventilation time was 8-10 h every night. Results: There were significant differences in the clinical symptoms, acute exacerbation and severity, health status, quality of life and lung function between the treatment group and the control group after 13 weeks of treatment (P <0.05). Conclusion: Tiotropium bromide(136310-93-5) combined with BiPAP can significantly improve the symptoms and improve the quality of life in patients with stable COPD. It has certain clinical value and has a positive effect on the reduction of lung function in COPD patients.

Address:211#Zhengfeng Building,Huanbaokejiyuan, Gaoxinkaifaqu, Jinan,250100,China TEL:086-531-82375818 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved